Stocks
Boston Scientific Financial Statements (BSX) |
||||||||||
| Boston Scientificsmart-lab.ru | % | 2020 | 2021 | 2022 | 2023 | 2023 | LTM ? | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Report date | 23.02.2021 | 23.02.2022 | 23.02.2023 | 20.02.2024 | 21.02.2024 | 01.11.2024 | ||||
| Currency | USD | USD | USD | USD | USD | USD | ||||
| Financial report URL | ||||||||||
| Revenue, bln rub | ? | 9 913 | 11 888 | 12 682 | 14 240 | 14 240 | 15 910 | |||
| Operating Income, bln rub | 1 044 | 2 043 | 1 649 | 2 343 | 2 343 | 2 757 | ||||
| EBITDA, bln rub | ? | 1 511 | 2 518 | 2 741 | 3 620 | 3 453 | 3 737 | |||
| Net profit, bln rub | ? | -140.0 | 1 041 | 698.0 | 1 593 | 1 593 | 1 789 | |||
| OCF, bln rub | ? | 1 508 | 1 870 | 1 526 | 2 503 | 2 503 | -1 140 913 | |||
| CAPEX, bln rub | ? | 376.0 | 554.0 | 612.0 | 800.0 | 800.0 | 1 059 | |||
| FCF, bln rub | ? | 1 132 | 1 316 | 914.0 | 1 703 | 1 703 | -1 141 972 | |||
| Dividend payout, bln rub | 28.0 | 55.0 | 55.0 | 28.0 | 28.0 | 23.0 | ||||
| Ordinary share dividend yield, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | ||||
| Dividend payout ratio, % | 0.00% | 5.28% | 7.88% | 1.76% | 1.76% | 1.29% | ||||
| OPEX, bln rub | 5 719 | 6 304 | 6 646 | 7 478 | 7 478 | 7 722 | ||||
| Cost of production, bln rub | 3 510 | 3 760 | 4 003 | 4 345 | 4 345 | 5 452 | ||||
| R&D, bln rub | 1 143 | 1 204 | 1 323 | 1 414 | 1 414 | 1 519 | ||||
| Interest expenses, bln rub | 361.0 | 341.0 | 470.0 | 265.0 | 265.0 | 290.0 | ||||
| Assets, bln rub | 30 778 | 32 230 | 32 470 | 35 136 | 35 136 | 38 078 | ||||
| Net Assets, bln rub | ? | 15 327 | 16 623 | 17 574 | 19 281 | 19 282 | 20 708 | |||
| Debt, bln rub | 9 539 | 9 451 | 9 282 | 9 492 | 9 492 | 11 258 | ||||
| Cash, bln rub | 1 734 | 1 925 | 928.0 | 865.0 | 865.0 | 2 502 | ||||
| Net debt, bln rub | 7 805 | 7 526 | 8 354 | 8 627 | 8 627 | 8 756 | ||||
| Ordinary share price, rub | 36.0 | 42.5 | 46.3 | 57.8 | 57.8 | 52.5 | ||||
| Number of ordinary shares, mln | 1 417 | 1 422 | 1 431 | 1 453 | 1 453 | 1 473 | ||||
| Market cap, bln rub | 50 930 | 60 419 | 66 189 | 83 998 | 83 998 | 77 346 | ||||
| EV, bln rub | ? | 58 735 | 67 945 | 74 543 | 92 625 | 92 625 | 86 102 | |||
| Book value, bln rub | -540 | -1 485 | -1 249 | -1 109 | -1 108 | -79 | ||||
| EPS, rub | ? | -0.10 | 0.73 | 0.49 | 1.10 | 1.10 | 1.21 | |||
| FCF/share, rub | 0.80 | 0.93 | 0.64 | 1.17 | 1.17 | -775.4 | ||||
| BV/share, rub | -0.38 | -1.04 | -0.87 | -0.76 | -0.76 | -0.05 | ||||
| EBITDA margin, % | ? | 15.2% | 21.2% | 21.6% | 25.4% | 24.2% | 23.5% | |||
| Net margin, % | ? | -1.41% | 8.76% | 5.50% | 11.2% | 11.2% | 11.2% | |||
| FCF yield, % | ? | 2.22% | 2.18% | 1.38% | 2.03% | 2.03% | -1 476% | |||
| ROE, % | ? | -0.91% | 6.26% | 3.97% | 8.26% | 8.26% | 8.64% | |||
| ROA, % | ? | -0.45% | 3.23% | 2.15% | 4.53% | 4.53% | 4.70% | |||
| P/E | ? | -363.8 | 58.0 | 94.8 | 52.7 | 52.7 | 43.2 | |||
| P/FCF | 45.0 | 45.9 | 72.4 | 49.3 | 49.3 | -0.07 | ||||
| P/S | ? | 5.14 | 5.08 | 5.22 | 5.90 | 5.90 | 4.86 | |||
| P/BV | ? | -94.3 | -40.7 | -53.0 | -75.7 | -75.8 | -979.1 | |||
| EV/EBITDA | ? | 38.9 | 27.0 | 27.2 | 25.6 | 26.8 | 23.0 | |||
| Debt/EBITDA | 5.17 | 2.99 | 3.05 | 2.38 | 2.50 | 2.34 | ||||
| R&D/CAPEX, % | 304.0% | 217.3% | 216.2% | 176.8% | 176.8% | 143.4% | ||||
| CAPEX/Revenue, % | 3.79% | 4.66% | 4.83% | 5.62% | 5.62% | 6.66% | ||||
| Boston Scientific shareholders | ||||||||||
